{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-050440","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.677926+00:00","generated_at":"2026-06-10T07:31:13.305146+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"KalVista stockholders approve officer exculpation amendment, elect directors","bullets":["Approved certificate of amendment to limit officer liability under Delaware law (20.2M for, 2.5M against).","Elected Patrick Treanor and Edward W. Unkart as Class II directors for three-year terms.","Ratified Deloitte & Touche as independent auditor for FY ending April 30, 2024 (30.8M for, 1.6K against).","Non-binding advisory vote on named executive officer compensation passed (20.0M for, 2.7M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-050440","json":"https://secwatch.observer/filing/0000950170-23-050440.json","markdown":"https://secwatch.observer/filing/0000950170-23-050440.md","text":"https://secwatch.observer/filing/0000950170-23-050440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/kalv-20230926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:31:13.305146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"526c523c31e45f3c5f60e5fdf713bb4517eb9047","claim":"KalVista Pharmaceuticals, Inc.: Certificate of amendment to certificate of incorporation to permit exculpation of certain officers from liability in specific circumstances (effective 2023-09-26).","evidence_excerpt":"the Company’s stockholders approved a certificate of amendment (the “Certificate of Amendment”) to the Company’s certificate of incorporation to permit the exculpation of certain of the Company’s officers from liability in specific circumstances.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-26"}],"fact_type":"governance_change"},{"claim_id":"328e0df4f97d5ce1f324202c087639282621b737","claim":"KalVista Pharmaceuticals, Inc. shareholders approved Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law at the 2023-09-26 meeting.","evidence_excerpt":"4. Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,203,486 2,450,421 1,385 8,184,921","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-26"}],"fact_type":"shareholder_vote"},{"claim_id":"43db1214751169f903e5353c70ad76963886505d","claim":"KalVista Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024 at the 2023-09-26 meeting.","evidence_excerpt":"2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024: Shares For Shares Against Shares Abstaining Broker Non-Votes 30,837,741 1,624 848 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-26"}],"fact_type":"shareholder_vote"},{"claim_id":"5cdb5fb0521b3283edaf3544901fb4722c4c5a28","claim":"KalVista Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers at the 2023-09-26 meeting.","evidence_excerpt":"3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,001,348 2,652,134 1,810 8,184,921","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-26"}],"fact_type":"shareholder_vote"},{"claim_id":"a22a81376373f16fe614144828ad215e62895c6c","claim":"KalVista Pharmaceuticals, Inc. shareholders approved Election of two Class II directors at the 2023-09-26 meeting.","evidence_excerpt":"On September 26, 2023, the Company held its 2023 Annual Meeting of Stockholders (“ Annual Meeting ”) and the following proposals were adopted: 1. Election of two Class II directors, Patrick Treanor and Edward W. Unkart (each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified): Nominees Shares For Shares Against Shares Abstaining Broker Non-Votes Patrick Treanor 15,931,760 6,722,475 1,058 8,184,920 Edward W. Unkart 15,154,122 7,499,378 1,791 8,184,922","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023050440/0000950170-23-050440-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-26"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}